by Stacey Hawkins | Feb 19, 2020 | Immunotherapies
Chimeric antigen receptor T-cells (CAR-Ts), reviewed last week, are a powerful new weapon for oncologists to use in their fight against cancer. These engineered T-cells are designed to home in on and kill malignant cells, and have proven highly effective at treating... 
by Stacey Hawkins | Feb 10, 2020 | Immunotherapies
The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—Kymriah (Novartis; Basel, Switzerland) and Yescarta—(Gilead; Foster City, CA) were approved in 2017, and remain one of the hottest immunotherapies on the market today. They work by... 
by Stacey Hawkins | Jan 22, 2019 | Immunotherapies
Further Down The Cancer Treatment Road With CARs Chimeric antigen receptor (CAR) T-cell therapies have captured the imagination of both scientists and the public. The ability to genetically alter a patient’s own cells to fight cancer has revolutionized the treatment... by Stacey Hawkins | Oct 11, 2018 | Immunotherapies
A Killer(-T) Nobel Prize In Medicine On October 1, James Allison, now at the M.D. Anderson Cancer Center in Houston, and Tasuku Honjo, now at Kyoto University, won the 2018 Nobel Prize in Physiology or Medicine. The two scientists discovered the basis for today’s... 
by Stacey Hawkins | Aug 9, 2018 | Immunotherapies
What Can’t These Little Dudes Do? When last we met, we discussed the fundamentals of monoclonal (mAb) therapies and looked at two recent advances: antibody-drug conjugates and bispecific antibodies. This week continues our adventure in antibody innovation by... 
by Stacey Hawkins | Aug 2, 2018 | Immunotherapies
Attack Of The Mono- & Polyclonals Monoclonal antibody (mAb) therapeutics burst onto the healthcare scene twenty years ago. They remain one of the most versatile and effective therapies available for a whole range of diseases including different types of cancers,...
